Candel Therapeutics Inc’s filing revealed that its Chief Medical Officer Nichols William Garrett unloaded Company’s shares for reported $0.4 million on Mar 18 ’25. In the deal valued at $8.76 per share,45,316 shares were sold. As a result of this transaction, Nichols William Garrett now holds 52,493 shares worth roughly $0.3 million.
Then, Barone Francesca sold 32,146 shares, generating $281,673 in total proceeds. Upon selling the shares at $8.76, the Chief Scientific Officer now owns 96,527 shares.
Before that, Tak Paul Peter sold 25,772 shares. Candel Therapeutics Inc shares valued at $226,023 were divested by the Chief Executive Officer at a price of $8.77 per share. As a result of the transaction, Tak Paul Peter now holds 226,140 shares, worth roughly $1.29 million.
Citigroup initiated its Candel Therapeutics Inc [CADL] rating to a Buy in a research note published on February 20, 2025; the price target was $25. A number of analysts have revised their coverage, including Canaccord Genuity’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. BofA Securities began covering CADL with “Buy” recommendation on February 07, 2025. H.C. Wainwright started covering the stock on December 02, 2022. It rated CADL as “a Buy”.
Price Performance Review of CADL
On Monday, Candel Therapeutics Inc [NASDAQ:CADL] saw its stock jump 6.54% to $5.70. Over the last five days, the stock has gained 13.77%. Candel Therapeutics Inc shares have fallen nearly -34.33% since the year began. Nevertheless, the stocks have fallen -59.29% over the past one year.
How much short interest is there in Candel Therapeutics Inc?
A steep rise in short interest was recorded in Candel Therapeutics Inc stocks on 2025-04-30, growing by 0.92 million shares to a total of 5.39 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 4.47 million shares. There was a rise of 17.13%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 19, 2021 when BMO Capital Markets began covering the stock and recommended ‘”an Outperform”‘ rating along with a $18 price target.
